Suppr超能文献

脂多糖受体CD14的两种可溶性形式:正常人单核细胞的特性及释放

The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes.

作者信息

Durieux J J, Vita N, Popescu O, Guette F, Calzada-Wack J, Munker R, Schmidt R E, Lupker J, Ferrara P, Ziegler-Heitbrock H W

机构信息

Department of Research, University Hospital, Basel.

出版信息

Eur J Immunol. 1994 Sep;24(9):2006-12. doi: 10.1002/eji.1830240911.

Abstract

CD14, a glycolipid-anchored membrane glycoprotein, acts as a high affinity lipopolysaccharide receptor on leukocytes. We previously reported that the Mono-Mac-6 cell line releases two different soluble forms of CD14 (sCD14) (Labeta et al., Eur. J. Immunol. 1993. 23: 2144). Here we show that the two sCD14, which we now refer to as sCD14 alpha (low M(r)) and sCD14 beta (high M(r)), are also synthesized and released by normal human monocytes and present in normal plasma. Their mechanism of release was examined by using the Mono-Mac-6 cell line, chinese hamster ovary cell (CHO)/CD14+ transfectants and plasma from paroxysmal nocturnal hemoglobinuria (PNH) patients. It was found that: (1) sCD14 beta is released faster than sCD14 alpha and that the release of the latter is a lengthy process. (2) Monensin blocked the biosynthesis of membrane-bound CD14 (mCD14) and sCD14, additionally, a 50-kDa CD14 polypeptide accumulated in the cell lysate, suggesting that the different forms of CD14 may have a common precursor. (3) Monensin also blocked the release of sCD14 alpha from surface-labeled cells, suggesting that conversion of mCD14 to sCD14 alpha involves a mechanism of endocytosis followed by exocytosis. Interestingly, (4) sCD14 alpha and sCD14 beta were detected in PNH plasma, indicating that sCD14 alpha may also derive from an endogenous pathway. (5) Phospholipase C-released CD14 was identical in size to mCD14, thus differed from sCD14 beta by approximately 2000, indicating that release of sCD14 beta involves further processing. (6) CHO cells transfected with a CD14 cDNA coding for an eight C-terminal amino acids shorter product released an sCD14 beta-like form; thus absence of the eight C-terminal amino acids prevented mCD14 expression but not the secretion of sCD14 beta. The characterization of sCD14 alpha and sCD14 beta reported here may be useful for better understanding of variations in sCD14 levels in pathological conditions and the contribution of each sCD14 in sepsis and other, as yet unknown functions.

摘要

CD14是一种糖脂锚定的膜糖蛋白,在白细胞上作为高亲和力脂多糖受体发挥作用。我们之前报道过,Mono-Mac-6细胞系可释放两种不同的可溶性CD14(sCD14)形式(拉贝塔等人,《欧洲免疫学杂志》,1993年。23:2144)。在此我们表明,这两种sCD14,我们现在将其称为sCD14α(低分子量)和sCD14β(高分子量),也由正常人单核细胞合成并释放,且存在于正常血浆中。我们利用Mono-Mac-6细胞系、中国仓鼠卵巢细胞(CHO)/CD14+转染细胞以及阵发性夜间血红蛋白尿(PNH)患者的血浆研究了它们的释放机制。结果发现:(1)sCD14β的释放速度比sCD14α快,且后者的释放是一个漫长的过程。(2)莫能菌素阻断了膜结合CD14(mCD14)和sCD14的生物合成,此外,细胞裂解物中积累了一种50 kDa的CD14多肽,这表明不同形式的CD14可能有一个共同的前体。(3)莫能菌素也阻断了表面标记细胞中sCD14α的释放,这表明mCD14向sCD14α的转化涉及一种内吞作用后再外排的机制。有趣的是,(4)在PNH血浆中检测到了sCD14α和sCD14β,这表明sCD14α也可能源自内源性途径。(5)磷脂酶C释放的CD14在大小上与mCD14相同,因此与sCD14β相差约2000,这表明sCD14β的释放涉及进一步加工。(6)用编码C末端八个氨基酸缺失产物的CD14 cDNA转染的CHO细胞释放出一种sCD14β样形式;因此,C末端八个氨基酸的缺失阻止了mCD14的表达,但不影响sCD14β的分泌。本文报道的sCD14α和sCD14β的特性可能有助于更好地理解病理状态下sCD14水平的变化以及每种sCD14在败血症和其他未知功能中的作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验